Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy
Source: Understanding and Implementing the AASLD’s HBV Practice Guidelines and Other Recent Guidelines and Recommendations on the Diagnosis, Management, and Treatment of Hepatitis B

Slideset

Slideset: Hepatitis B Screening, Diagnosis, and Treatment Candidacy

In this downloadable slideset, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, reviews the latest guideline recommendations on HBV screening, diagnosis, and treatment candidacy.
Format: Microsoft PowerPoint (.ppt)
File size: 5.78 MB
Date posted: 11/11/2010
  • My Approach to Identifying Treatment Candidates and Maintaining Patients on Long-term HBV Therapy

    Anna S. F. Lok MD - 6/19/2014    9 comments / Last Comment: 1/3/2015
    I find it helpful to discuss the impact of treatment on liver fibrosis/cirrhosis and hepatocellular carcinoma with patients, which motivates some to initiate and adhere to their long-term treatment.
  • Genotype 3 HCV: Still Difficult to Treat?

    Jordan J. Feld MD, MPH - 2/10/2015    1 comment / Last Comment: 2/25/2015
    My take on how to manage genotype 3 HCV and how evolving therapeutic options will likely improve outcomes for treatment-experienced cirrhotic patients with genotype 3 HCV infection.
  • HCV Treatment in Liver Transplantation Recipients: My Take on the Latest HCV Guidance

    Nezam H. Afdhal MD, FRCPI - 4/7/2015    1 comment / Last Comment: 4/13/2015
    In starting HCV treatment after liver transplant, how soon is soon enough?
  • Using Ledipasvir/Sofosbuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 Weeks With Ribavirin or 24 Weeks Without?

    Ira M. Jacobson MD - 3/23/2015    4 comments / Last Comment: 4/20/2015
    Although new data suggest comparable efficacy of ledipasvir/sofosbuvir with ribavirin for 12 weeks vs 24 weeks without ribavirin in genotype 1 cirrhotic, treatment-experienced patients, I am not convinced that shortening treatment is the best approach.
  • Using Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 or 24 Weeks, With or Without Ribavirin?

    Paul Y. Kwo MD - 4/8/2015    2 comments / Last Comment: 4/24/2015
    Until more data are available on the use of the 3-DAA regimen in genotype 1 cirrhotic, treatment-experienced patients, I prefer to err on the side of caution to maximize opportunity for achieving SVR.